Curasight has published the full data from an investigator-initiated phase II trial evaluating its uTRACE imaging technology in brain cancer patients in the peer-reviewed journal EJNMMI Research. The results – which were first reported in connection with an oral presentation at a conference last year – supports the strategy to develop uTRACE and the therapeutic uTREAT in parallel.
Read the full article at biostock.se:
https://www.biostock.se/en/2024/11/full-phase-ii-results-of-upar-pet-in-glioblastoma-published/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se
